logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9506066 B1

PDFFull Text
Date of Patent:
Nov. 29, 2016

Filed:

Dec. 02, 2014

Repressor on ifn-λ promoter and sirna against gata1, evi1, and crx to alter ifn-λ gene activity

Applicant:

Medical Diagnostic Laboratories, Llc, Hamilton, NJ (US);

Inventors:

Grant Gallagher, Milltown, NJ (US);

Joyce Eskdale, Milltown, NJ (US);

Rachael Siegel, Fords, NJ (US);

Assignee:

Medical Diagnostic Laboratories, LLC, Hamilton, NJ (US);

Attorney:

Siu K. Lo

Primary Examiner:

Sean McGarry

Int. Cl.
CPC ...
A61K 31/70 (2006.01); C07H 21/02 (2006.01); C07H 21/04 (2006.01); C12N 15/113 (2010.01); G01N 33/50 (2006.01); A61K 31/713 (2006.01); C12Q 1/68 (2006.01);
U.S. Cl.
CPC ...
C12N 15/1136 (2013.01); A61K 31/713 (2013.01); C12N 15/113 (2013.01); G01N 33/5044 (2013.01); C12N 2310/14 (2013.01);
Abstract

The present invention is directed to the identification of a novel repressor located between ˜1.2 kb to ˜1.6 kb from the translation start site of the IFN-λ1 promoter. The present invention provides a method of using siRNAs against ZEB1 (binds to the repressor region) and BLIMP-1 (binds outside the repressor region) and increases the promoter activity of IFN-λ1 (i.e., increases the production of IFN-λ1 protein). siRNAs against ZEB1 mRNA or BLIMP-1 mRNA increase IFN-λ1 gene activity. There is provided a therapeutic application of siRNAs against ZEB1 and BLIMP-1 mRNAs in treating a mammal (including a human) by increasing the production of IFN-λ1 protein that promotes an anti-viral response as well as treats asthma diseases and colon diseases.

Find Patent Forward Citations

Loading…